ERCC6/CSB gene polymorphisms and lung cancer risk
Hongxia Ma1, Zhibin Hu, Haifeng Wang
1Department of Epidemiology and Biostatistics, Cancer Research Center of Nanjing Medical University, School of Public Health, 140 Han-Zhong Road, Nanjing, Jiangsu 210029, China.
Cancer Letters
|September 16, 2008
Summary
Genetic variants in the ERCC6 gene may increase lung cancer risk. Combined variations in multiple ERCC6 loci are associated with higher susceptibility to smoking-related lung cancer in a Chinese population.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- Nucleotide excision repair (NER) enzymes remove DNA damage from environmental carcinogens.
- Cockayne syndrome complementation group B (CSB), encoded by ERCC6, is crucial for recruiting NER factors to DNA damage sites.
- Genetic variations in ERCC6 may influence DNA repair efficiency and lung cancer risk.
Purpose of the Study:
- To investigate the association between ERCC6 genetic variants and the risk of smoking-related lung cancer.
- To determine if single nucleotide polymorphisms (SNPs) in ERCC6 impact lung cancer susceptibility.
Main Methods:
- Genotyping of eight tagging SNPs and three functional SNPs in the ERCC6 gene.
- Case-control study involving 500 lung cancer cases and 517 controls from a Chinese population.
- Statistical analysis of single SNP effects and combined genotype associations.
Main Results:
- No single ERCC6 SNP showed a significant association with lung cancer risk.
- Combined variants in four specific ERCC6 loci (rs2228526, rs4253160, rs12571445, rs3793784) were linked to a significantly increased lung cancer risk.
- Individuals with three or more variant alleles in these loci had an adjusted odds ratio of 1.35 (95% CI, 1.04-1.75).
Conclusions:
- Multiple ERCC6 gene loci may jointly contribute to lung cancer susceptibility.
- These findings suggest a potential role for combined ERCC6 variants in identifying individuals at higher risk for smoking-related lung cancer.
- Further validation is needed to confirm the contribution of ERCC6 variants to lung cancer risk.
More Related Videos
06:21Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
10:21Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
Published on: September 20, 2024
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...